Spexis AG, a clinical-stage biopharmaceutical company, engages in the development of therapies for rare disease and oncology patients. Its products pipeline include ColiFin for the treatment of cystic fibrosis infections; inhaled murepavadin, an outer membrane protein targeting antibiotic to treat Pseudomonas infections in people with cystic fibrosis; EBX-002 for non-tuberculous mycobacterial lung infections; POL6014, an inhaled inhibitor of neutrophil elastase to treat cystic fibrosis and other neutrophilic lung diseases; Balixafortide for oncology/non oncology orphan indications; POL New CXCR4 for treating orphan hematological malignancies; and OMPTA BamA/LptA programs. The company is headquartered in Allschwil, Switzerland.